France: Egle Therapeutics, an emerging biotechnology company focused on developing immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, has completed a €40m (US$46.4m) Series A financing….
France: Egle Therapeutics, an emerging biotechnology company focused on developing immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, has completed a €40m (US$46.4m) Series A financing….
…
Rankings & Reports
M&A
Equity
Healthcare Investing Review
Healthcare Real Assets Report
Resources & Events
Resource Hub
Sector Events
Private Capital Conference
Real Assets Conference


